The cumulative incidence of relapse after hHSCT in non-expressed vs. expressed KIR3DL1 allotypes did not differ when all patients were included (Figure 4b and Figure S2a) or restricted to patients treated for a lymphoid neoplasm (Figure 4b and Figure S2b). The gene discussed is KIR3DL1; the disease is lymphoid neoplasm.